BioXcel Therapeutics Toekomstige groei
Future criteriumcontroles 2/6
BioXcel Therapeutics is forecast to grow earnings and revenue by 17.2% and 57.7% per annum respectively while EPS is expected to grow by 43.8% per annum.
Belangrijke informatie
17.2%
Groei van de winst
43.8%
Groei van de winst per aandeel
| Biotechs winstgroei | 27.1% |
| Inkomstengroei | 57.7% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 21 Oct 2024 |
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 20 | -71 | -66 | -70 | 3 |
| 12/31/2025 | 10 | -83 | -77 | -98 | 5 |
| 12/31/2024 | 5 | -78 | -85 | -92 | 5 |
| 6/30/2024 | 2 | -108 | -105 | -105 | N/A |
| 3/31/2024 | 2 | -153 | -120 | -120 | N/A |
| 12/31/2023 | 1 | -179 | -155 | -155 | N/A |
| 9/30/2023 | 1 | -212 | -167 | -167 | N/A |
| 6/30/2023 | 1 | -203 | -160 | -160 | N/A |
| 3/31/2023 | 1 | -187 | -155 | -155 | N/A |
| 12/31/2022 | 0 | -166 | -135 | -135 | N/A |
| 9/30/2022 | 0 | -137 | -117 | -117 | N/A |
| 6/30/2022 | N/A | -122 | -106 | -106 | N/A |
| 3/31/2022 | N/A | -112 | -95 | -95 | N/A |
| 12/31/2021 | N/A | -107 | -83 | -82 | N/A |
| 9/30/2021 | N/A | -102 | -83 | -82 | N/A |
| 6/30/2021 | N/A | -100 | -82 | -81 | N/A |
| 3/31/2021 | N/A | -94 | -74 | -74 | N/A |
| 12/31/2020 | N/A | -82 | -67 | -66 | N/A |
| 9/30/2020 | N/A | -69 | -54 | -54 | N/A |
| 6/30/2020 | N/A | -54 | -42 | -42 | N/A |
| 3/31/2020 | N/A | -41 | -34 | -34 | N/A |
| 12/31/2019 | N/A | -33 | -28 | -27 | N/A |
| 9/30/2019 | N/A | -32 | -25 | -24 | N/A |
| 6/30/2019 | N/A | -28 | -20 | -19 | N/A |
| 3/31/2019 | N/A | -22 | -19 | -18 | N/A |
| 12/31/2018 | N/A | -19 | -14 | -14 | N/A |
| 9/30/2018 | N/A | -15 | -10 | -10 | N/A |
| 6/30/2018 | N/A | -11 | -8 | -7 | N/A |
| 3/31/2018 | N/A | -8 | N/A | -3 | N/A |
| 12/31/2017 | N/A | -5 | N/A | -2 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: BTAI is forecast to remain unprofitable over the next 3 years.
Winst versus markt: BTAI is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: BTAI is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: BTAI's revenue (57.7% per year) is forecast to grow faster than the US market (8.9% per year).
Hoge groei-inkomsten: BTAI's revenue (57.7% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if BTAI's Return on Equity is forecast to be high in 3 years time